Alnylam Pharmaceuticals
ALNY
#637
Rank
NZ$54.46 B
Marketcap
$420.71
Share price
-0.07%
Change (1 day)
74.75%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total liabilities

Total liabilities on the balance sheet as of December 2024 : NZ$7.26 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total liabilities are NZ$7.26 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Alnylam Pharmaceuticals - Total liabilities on balance sheet (from 2003 to 2024)

Total liabilities by year

Year Total liabilities Change
2024-12-31NZ$7.39 B15.52%
2023-12-31NZ$6.40 B9.77%
2022-12-31NZ$5.83 B30.45%
2021-12-31NZ$4.47 B34.99%
2020-12-31NZ$3.31 B133.32%
2019-12-31NZ$1.42 B249.15%
2018-12-31NZ$0.40 B26.53%
2017-12-31NZ$0.32 B-35%
2016-12-31NZ$0.49 B177.92%
2015-12-31NZ$0.17 B-2.72%
2014-12-31NZ$0.18 B0.09%
2013-12-31NZ$0.18 B-2.04%
2012-12-31NZ$0.18 B-11.18%
2011-12-31NZ$0.21 B-31.06%
2010-12-31NZ$0.30 B-27.07%
2009-12-31NZ$0.41 B-31.24%
2008-12-31NZ$0.60 B57.95%
2007-12-31NZ$0.38 B597.81%
2006-12-31NZ$55.11 M3.02%
2005-12-31NZ$53.5 M91.22%
2004-12-31NZ$27.97 M-70.61%
2003-12-31NZ$95.2 M140.05%
2002-12-31NZ$39.66 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
NZ$1.66 B-77.05%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$14.63 B 101.44%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$4.24 B-41.64%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$1.45 B-80.00%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$12.11 M-99.83%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$101.21 B 1,292.80%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NZ$99.56 B 1,270.09%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$58.52 B 705.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel